Succinate-Based Dietary Supplement for Menopausal Symptoms: A Pooled Analysis of Two Identical Randomized, Double-Blind, Placebo-Controlled Clinical Trials

Table 5

Plasma hormone concentrations.

Hormones	Time	Supplement n = 114	Placebo n = 113
Estradiol (pg/ml)	Initial	35.7 [28.4, 47.1]	42.3 [29.1, 52.6]	0.0187
	30 days	48.9 [35.3, 59.9]	41.1 [30.1, 52.8]	0.0123
	60 days	54.0 [42.0, 65.0]	40.4 [28.1, 50.4]	≤0.001
	90 days	58.0 [46.1, 58.6]	39.9 [27.2, 50.2]	≤0.001
		<0.05	<0.05
FSH (mIU/ml)	Initial	57.2 [40.6, 74.1]	51.5 [37.3, 68.4]	0.0938
	30 days	53.9 [40.9, 70.7]	52.0 [39.7, 70.1]	0.9291
	60 days	51.2 [38.1, 65.2]	50.8 [38.8, 71.3]	0.4594
	90 days	48.2 [37.1, 62.8]	50.2 [38.7, 68.5]	0.3131
		<0.05	>0.05
LH (mIU/ml)	Initial	31.1 [22.9, 38.9]	29.2 [21.8, 35.7]	0.1740
	30 days	30.5 [24.0, 39.0]	29.9 [22.2, 36.1]	0.4118
	60 days	29.9 [21.4, 35.4]	28.9 [22.7, 35.2]	0.8532
	90 days	28.3 [20.8, 34.1]	28.4 [22.0, 35.2]	0.6492
		<0.05	>0.05
Leptin (ng/ml) (0.5–13.8)	Initial	16.5 [11.9, 23.8]	15.4 [10.5, 24.2]	0.4509
	90 days	14.1 [10.5, 18.2]	15.3 [11.3, 27.8]	0.0274
		>0.05	>0.05

Indicated values are (Ме [Q₁, Q₃]). : supplement versus placebo (Mann–Whitney test); : initial versus 90 days (Friedman test, Mann–Whitney test). Bold numbers indicate statistically significant values.